Cushing's Syndrome
Guidance for pituitary disease management during COVID-19
The COVID-19 pandemic presents substantial challenges for pituitary disease management, and clinicians should consider local conditions and hospital resources when opting for surgery vs. medical management, according to new guidance.
‘Striking’ BMD increase follows surgical remission in endogenous Cushing’s syndrome
A cohort of adults with endogenous Cushing’s syndrome experienced a high rate of bone turnover immediately after surgical remission, resulting in a “striking” net increase in bone mineral density for most patients, researchers reported.
AACE statement offers COVID-19 guidance for people with adrenal insufficiency, Cushing’s syndrome
People with adrenal insufficiency or uncontrolled Cushing’s syndrome are at greater risk for death from a respiratory-related infection, such as COVID-19, and should observe several key recommendations to avoid complications, according to a new position statement issued by the American Association of Clinical Endocrinologists.
FDA approves oral treatment for Cushing’s disease
The FDA has approved the nonsteroidal corticosteroid biosynthesis inhibitor osilodrostat for adults with Cushing’s disease who cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease, according to an agency press release.
New treatments offer ‘glimmers of optimism,’ possible cure for Cushing’s disease
More than a century has passed since neurosurgeon and pathologist Harvey Cushing described the disease that would eventually bear his name, but only recently have several key discoveries offered patients with the condition real hope for a cure.
Small adrenal tumors in primary aldosteronism may signal subclinical Cushing’s syndrome
In rare cases of a concurrence of primary aldosteronism and subclinical Cushing’s syndrome, the two conditions did not exhibit any additive or synergic impact on glucose or potassium metabolism or maximum tumor diameter, according to findings published in BMC Endocrine Disorders.
Pasireotide reduces pituitary tumor volume in Cushing’s disease
Most adults with persistent or recurrent Cushing’s disease treated with the somatostatin analogue pasireotide experienced a measurable decrease in MRI-detectable pituitary tumor volume at 12 months, according to findings from a post hoc analysis of a randomized controlled trial.
Cabergoline may increase recurrence risk after remission in Cushing’s disease
Use of the dopamine agonist cabergoline during conventional fractionated radiotherapy to treat Cushing’s disease may be associated with a higher disease recurrence rate after an initial remission, according to findings published in Clinical Endocrinology.